Behavioral Processes Underlying Reward Processing in Depression
Completed
Conditions studied: Major Depressive Disorder, Bipolar Disorder
In brief
The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.
Key facts
- Study ID
- NCT00205933
- Run by
- Affective Neuroscience Laboratory
- People needed
- 78
- Starts
- 2004-04-01
- Expected to finish
- 2007-06-01
- Last updated by the study team
- 2007-12-06
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Depressed participants:
- Right-handed
- DSM-IV diagnosis of MDD
- Score of at least 17 on the 21-item HAM-D scale
- Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
- No current or past history of MDD with psychotic features
- Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
- Absence of significant medical conditions
- Absence of ECT in the previous 6 months
- Ability to provide informed consent/authorization
- Bipolar participants:
- Both genders and all ethnic origins
- Age between 18 and 64
- Right-handed
- DSM-IV diagnosis of Bipolar Disorder I or II
- Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
- Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
- No current or past history of MDD with psychotic features
- Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
- Absence of significant medical conditions
- Absence of ECT in the previous 6 months
- Ability to provide informed consent/authorization
- Control Participants:
- Right-handed
- Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
You may not qualify if…
- Left-handed/ambidextrous
- Evidence of neurological illness
- Current alcohol or substance abuse
- Serious suicide or homicide risk
Where it is running
- The Depression Clinical and Research Program, Massachusetts General Hospital — Boston, Massachusetts, United States
- Affective Neuroscience Laboratory, Department of Psychology, Harvard University — Cambridge, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.